Sam­sung Bi­o­log­ics touts Q2 per­for­mance af­ter ex­pand­ing deals with big phar­mas

CD­MO Sam­sung Bi­o­log­ics said its rev­enue jumped 33% in the sec­ond quar­ter, dur­ing which it an­nounced deals with ma­jor drug­mak­ers like Pfiz­er and No­var­tis

The CD­MO said rev­enue is up KRW 866.2 bil­lion ($679.5 mil­lion), a 33% in­crease from the sec­ond quar­ter of last year, which was KRW 651.4 bil­lion ($510.9 mil­lion). Its op­er­at­ing prof­it soared 49% to KRW 253.4 bil­lion ($198.7 mil­lion) in the sec­ond quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER